Lead investor confirmed his intention to maintain his current shareholdings. Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next ...

Novartis announced today that Cosentyx ®  (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis ...

Blue Cross and Blue Shield of Minnesota announced continued progress in its Excellence in Quality and Outcomes (EQO) Certification Program, a key initiative designed to strengthen healthcare quality ...

Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) ...

Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Mawer Investment Management Ltd, dated 11 March ...

National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50; Many respondents report undergoing ...

Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI. Tevogen.AI was built ...

ProText Mobility Inc. (OTC: TXTM), a biotech company and leader in blockchain-enabled asset tokenization and compliant Real-World Asset (RWA) solutions, is excited to provide an important strategic ...

Standard Imaging Captures Only a Fraction of It The Endothelial Glycocalyx: A Microscopic Lining That Helps Regulate How Blood Moves Through the Smallest Vessels How Patented Microfluidic Chip ...

Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on March 10, 2026 to three new employees as ...

Positions Lifeward as a diversified biomedical innovation company with clear path to profitability. Integration of Oramed’s POD™ oral delivery technology expands Lifeward into ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod ...